SLXNW

Silexion Therapeutics Corp

• TipRanks·10/28 20:16

  Silexion registers to sell 8.81M ordinary shares for holders

• TipRanks·10/26 20:31

  Silexion Therapeutics Shareholders Approve Major Capital Restructuring

• TipRanks·09/30 13:17

  Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial

• NASDAQ·09/30 13:16

  Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer

• TipRanks·09/30 12:25

  Silexion announces first patient dosed in Phase 2/3 trial of SIL204

• TipRanks·09/29 14:58

  Silexion Therapeutics Announces Warrant Inducement Financing Deal

• NASDAQ·09/28 16:36

  Silexion Advances SIL204 With Positive Findings On Systemic Uptake In KRAS-Driven Cancers

• TipRanks·09/28 13:27

  Silexion Highlights Positive Translational Data for RNAi Oncology

• TipRanks·09/28 13:01

  Silexion Therapeutics reports preclinical findings for SIL204

• TipRanks·09/25 20:57

  Silexion Therapeutics Shareholders Reject Capital Structure Changes

• TipRanks·09/25 20:50

  Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice

• NASDAQ·09/10 18:49

  5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus

• NASDAQ·09/04 13:45

  Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs

• TipRanks·08/25 13:00

  After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

• TipRanks·08/21 21:03

  Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal